LON:ONC Oncimmune (ONC) Share Price, News & Analysis → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free ONC Stock Alerts GBX 22.81 -1.29 (-5.36%) (As of 05:55 AM ET) Add Compare Share Share Today's Range 22.81▼ 22.8150-Day Range 16.80▼ 30.4252-Week Range 13▼ 45Volume110 shsAverage Volume74,486 shsMarket Capitalization£16.91 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Oncimmune alerts: Email Address Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Oncimmune Stock (LON:ONC)Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.Read More ONC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONC Stock News HeadlinesMarch 19, 2024 | wsj.comOncimmune Holdings PLCMarch 2, 2024 | finance.yahoo.comOncimmune Holdings Full Year 2023 Earnings: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)May 3, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.February 15, 2024 | reuters.comCancer test firm Freenome raises $254 mln in fresh fundingFebruary 14, 2024 | msn.comActivist investor Kelso gains board seats at The Works as it tries to enhance shareholder valueDecember 2, 2023 | proactiveinvestors.com.auOncimmune seeing commercial traction as it inks new deals with big pharma companiesSeptember 26, 2023 | yahoo.comThe Unique Use of Liquid BiopsyAugust 1, 2023 | marketwatch.comOncimmune's Acting CEO Ron Kirschner Steps Down, Takes COO Role; Gouldstone Starts as CEOMay 3, 2024 | Crypto Swap Profits (Ad)Did You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.July 14, 2023 | marketwatch.comOncimmune Shares Fall As Company Lowers FY 2022 Revenue ResultJuly 12, 2023 | lse.co.ukOncimmune names chief executive successor, while finance chief leavesJuly 12, 2023 | marketwatch.comOncimmune Holdings Appoints Martin Gouldstone CEO; CFO Matthew Hall to Step DownJune 23, 2023 | lse.co.ukOncimmune Holdings shakes up leadership and unveils new growth planJune 23, 2023 | marketwatch.comOncimmune CEO Adam Hill to Step Down; Sees Tough End to FY 2023May 31, 2023 | lse.co.ukOncimmune shares plummet as interim revenue falls by fifthMay 31, 2023 | marketwatch.comOncimmune Shares Fall on 1H Pretax LossMay 22, 2023 | lse.co.ukOncimmune sells two subsidiaries to Freenome for GBP13 millionMay 22, 2023 | markets.businessinsider.comFREENOME ACQUIRES GLOBAL IMMUNODIAGNOSTICS DEVELOPER ONCIMMUNE LTDMay 22, 2023 | marketwatch.comOncimmune Eases Going-Concern Risk With Sale of Two Subsidiaries for GBP13 MlnApril 28, 2023 | marketwatch.comThe Comprehensive Guide to the Cancer Biopsy Market: Trends and Revenue Forecast with predicted CAGR of 4.2% from 2023-2030April 22, 2023 | marketwatch.comCancer Biopsy Market Outlook by 2031April 12, 2023 | finance.yahoo.comOncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual ConferenceFebruary 28, 2023 | proactiveinvestors.comOncimmune delivering top-line growthFebruary 27, 2023 | marketwatch.comOncimmune Shares Fall After Going Concern Warning, Pretax LossFebruary 20, 2023 | lse.co.ukCORRECT: Oncimmune works with Siemens Healthineers on cancer therapyJanuary 25, 2023 | theguardian.comRichard Sharp: BBC chair was shareholder in firm awarded £600k while he was a No 10 adviserJanuary 2, 2023 | finance.yahoo.comInvestors in Oncimmune Holdings (LON:ONC) have unfortunately lost 67% over the last yearSee More Headlines Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncimmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2018Today5/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:ONC CUSIPN/A CIKN/A Weboncimmune.com Phone+44-115-8231869FaxN/AEmployees52Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.08) Trailing P/E RatioN/A Forward P/E Ratio27.90 P/E GrowthN/ANet Income£-6,150,000.00 Net Margins356.25% Pretax MarginN/A Return on Equity-760.96% Return on Assets-26.38% Debt Debt-to-Equity Ratio806.85 Current Ratio3.91 Quick Ratio0.63 Sales & Book Value Annual Sales£1.15 million Price / Sales15.54 Cash FlowGBX 2.02 per share Price / Cash Flow11.96 Book ValueGBX 1 per share Price / Book24.10Miscellaneous Outstanding Shares74,140,000Free FloatN/AMarket Cap£17.87 million OptionableNot Optionable Beta1.12 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Martin John Gouldstone (Age 58)CEO & Director Mr. Martin HudsonFinance DirectorMr. Ron Kirschner (Age 45)COO, General Counsel & Company Secretary Prof. Tariq Sethi B.Sc.FRCP, M.A., M.D., Ph.D., Chief Scientific OfficerMs. Cléa RosenfeldHead of Investor RelationsMr. Maarten BrusseChief Commercial Officer of AsiaMore ExecutivesKey CompetitorsOxford BioDynamicsLON:OBDDestiny PharmaLON:DESTSareumLON:SAROptiBiotix HealthLON:OPTISkinBioTherapeuticsLON:SBTXView All CompetitorsInsidersMartin GouldstoneBought 36,023 shares on 12/8/2023Total: £972,621.00 ($27.00/share)Adam HillBought 48,370 shares on 6/5/2023Total: £1.02 M ($21.00/share)View All Insider Transactions ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed in 2024? Oncimmune's stock was trading at GBX 25.20 at the beginning of 2024. Since then, ONC shares have decreased by 4.4% and is now trading at GBX 24.10. View the best growth stocks for 2024 here. How were Oncimmune's earnings last quarter? Oncimmune Holdings plc (LON:ONC) announced its earnings results on Tuesday, February, 13th. The company reported ($5.70) earnings per share for the quarter. The firm earned $0.08 million during the quarter. Oncimmune had a net margin of 356.25% and a negative trailing twelve-month return on equity of 760.96%. What other stocks do shareholders of Oncimmune own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncimmune investors own include Actinium Pharmaceuticals (ATNM), Digi International (DGII), SeaChange International (SEAC), SMTC (SMTX), Axsome Therapeutics (AXSM), Chimerix (CMRX) and Constellation Pharmaceuticals (CNST). How do I buy shares of Oncimmune? Shares of ONC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:ONC) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncimmune Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
